On Tuesday, Recursion Pharmaceuticals (RXRX) stock reached a key performance benchmark, with its Relative Strength (RS) Rating rising into the 90-plus percentile with an improvement to 92, a rise from 64 the day before. This unique rating identifies technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks…
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。